Robert L. Walker

Robert L. Walker

Auto-generated profile, based on publicly available information

Robert L. Walker

Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Nature
Verified
Journal Article
Closed access
PDF file
NWNiek van Wietmarschen
Niek van Wietmarschen
SSSriram Sridharan
Sriram Sridharan
WNWilliam J. Nathan
William J. Nathan
ATAnthony Tubbs
Anthony Tubbs
ECEdmond M. Chan
Edmond M. Chan
ANAndré Nussenzweig
André Nussenzweig

1 November 2003
Verified
Journal Article
Closed access
HCHeather E Cunliffe
Heather E Cunliffe
MRMarkus Ringnér
Markus Ringnér
SBSven Bilke
Sven Bilke
RWRobert L Walker
Robert L Walker
JCJennifer M Cheung
Jennifer M Cheung
PMPaul S Meltzer
Paul S Meltzer

2 July 2015 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
YGYevgeniy Gindin
Yevgeniy Gindin
YJYuan Jiang
Yuan Jiang
PFPrincy Francis
Princy Francis
RWRobert L. Walker
Robert L. Walker
OAOgan D. Abaan
Ogan D. Abaan
PMPaul S. Meltzer
Paul S. Meltzer
Osteosarcoma is the most common type of bone cancer in children and adolescents. Impaired differentiation of osteoblast cells is a distinguishing feature of this aggressive disease. As improvements in survival outcomes have largely plateaued, better understanding of the bone differentiation program may provide new treatment approaches. The miRNA cluster miR-23a~27a~24-2, particularly miR-23a, has been shown to interact with genes important for bone development. However, global changes in gene expression associated with functional gain of this cluster have not been fully explored. To better understand the relationship between miR-23a expression and bone cell differentiation, we carried out a large-scale gene expression analysis in HOS cells. Experimental results demonstrate that over-expression of miR-23a delays differentiation in this system. Downstream bioinformatic analysis identified miR-23a target gene connexin-43 (Cx43/GJA1), a mediator of intercellular signaling critical to osteoblast development, as acutely affected by miR-23a levels. Connexin-43 is up-regulated in the course of HOS cell differentiation and is down-regulated in cells transfected with miR-23a. Analysis of gene expression data, housed at Gene Expression Omnibus, reveals that Cx43 is consistently up-regulated during osteoblast differentiation. Suppression of Cx43 mRNA by miR-23a was confirmed in vitro using a luciferase reporter assay. This work demonstrates novel interactions between microRNA expression, intercellular signaling and bone differentiation in osteosarcoma.

1 April 2020 in Genetics
Verified
Journal Article
Open access
PDF file
KOKentaro Ohkuni
Kentaro Ohkuni
ESEvelyn Suva
Evelyn Suva
WAWei-Chun Au
Wei-Chun Au
RWRobert L Walker
Robert L Walker
RLReuben Levy-Myers
Reuben Levy-Myers
MBMunira A. Basrai
Munira A. Basrai
Centromeric localization of CENP-A (Cse4 in Saccharomyces cerevisiae, CID in flies, CENP-A in humans) is essential for faithful chromosome segregation. Mislocalization of overexpressed CENP-A contributes to aneuploidy in yeast, flies, and humans, and is proposed to promote tumorigenesis in human cancers. Hence, defining molecular mechanisms that promote or prevent mislocalization of CENP-A is an area of active investigation. In budding yeast, evolutionarily conserved histone chaperones Scm3 and chromatin assembly factor-1 (CAF-1) promote localization of Cse4 to centromeric and noncentromeric regions, respectively. Ubiquitin ligases, such as Psh1 and Slx5, and histone chaperones (HIR complex) regulate proteolysis of overexpressed Cse4 and prevent its mislocalization to noncentromeric regions. In this study, we have identified sumoylation sites lysine (K) 215/216 in the C terminus of Cse4, and shown that sumoylation of Cse4 K215/216 facilitates its genome-wide deposition into chromatin when overexpressed. Our results showed reduced levels of sumoylation of mutant Cse4 K215/216R/A [K changed to arginine (R) or alanine (A)] and reduced interaction of mutant Cse4 K215/216R/A with Scm3 and CAF-1 when compared to wild-type Cse4. Consistent with these results, levels of Cse4 K215/216R/A in the chromatin fraction and localization to centromeric and noncentromeric regions were reduced. Furthermore, in contrast to GAL-CSE4, which exhibits Synthetic Dosage Lethality (SDL) in psh1∆, slx5∆, and hir2∆ strains, GAL-cse4 K215/216R does not exhibit SDL in these strains. Taken together, our results show that deposition of Cse4 into chromatin is facilitated by its C-terminal sumoylation.

8 September 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
SGSheryl M. Gough
Sheryl M. Gough
LGLiat Goldberg
Liat Goldberg
MPMarbin Pineda
Marbin Pineda
RWRobert L. Walker
Robert L. Walker
YZYuelin J. Zhu
Yuelin J. Zhu
PAPeter D. Aplan
Peter D. Aplan
Key Points: An NUP98-PHF23 fusion collaborates with acquired Bcor and Jak/Stat mutations to produce a pro–B-1 ALL. Gene expression profile of murine pro–B-1 ALL resembles that of a subset of human ALL, suggesting some human ALLs arise from pro–B-1 B cells.

6 July 2006 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
JJJennifer Johnston
Jennifer Johnston
RWRobert L Walker
Robert L Walker
SDSean Davis
Sean Davis
FFFlavia Facio
Flavia Facio
JTJoyce T Turner
Joyce T Turner
LBLeslie G Biesecker
Leslie G Biesecker
Contiguous gene syndromes cause disorders via haploinsufficiency for adjacent genes. Some contiguous gene syndromes (CGS) have stereotypical breakpoints, but others have variable breakpoints. In CGS that have variable breakpoints, the extent of the deletions may be correlated with severity. The Greig cephalopolysyndactyly contiguous gene syndrome (GCPS-CGS) is a multiple malformation syndrome caused by haploinsufficiency of GLI3 and adjacent genes. In addition, non-CGS GCPS can be caused by deletions or duplications in GLI3. Although fluorescence in situ hybridisation (FISH) can identify large deletion mutations in patients with GCPS or GCPS-CGS, it is not practical for identification of small intragenic deletions or insertions, and it is difficult to accurately characterise the extent of the large deletions using this technique. We have designed a custom comparative genomic hybridisation (CGH) array that allows identification of deletions and duplications at kilobase resolution in the vicinity of GLI3. The array averages one probe every 730 bp for a total of about 14 000 probes over 10 Mb. We have analysed 16 individuals with known or suspected deletions or duplications. In 15 of 16 individuals (14 deletions and 1 duplication), the array confirmed the prior results. In the remaining patient, the normal CGH array result was correct, and the prior assessment was a false positive quantitative polymerase chain reaction result. We conclude that high-density CGH array analysis is more sensitive than FISH analysis for detecting deletions and provides clinically useful results on the extent of the deletion. We suggest that high-density CGH array analysis should replace FISH analysis for assessment of deletions and duplications in patients with contiguous gene syndromes caused by variable deletions.